The sad situation is that we are months away from any updates on...

The sad situation is that we are months away from any updates on current trials with most of the trial updates scheduled for H2 and more likely, in Q4 to early 2025. Plenty of time to drift back to 3c.

Very soon any profits made from the last Capital raise (at an average of 5.6c per share) will have been wiped out.

We all know by now that any announcements not to do with clinical trial updates is generally greeted by the market with drop in SP.

So cannot see any events in the next few months that can reverse the downward pressure on the share price. Not even a super green day on the ASX.

The question then, if it does go back to 3c, do you top up and average down? One thing for sure, any bad news released from IMU will see a severe punishment of the already diminished SP.

Lets hope that IMU can surprise the market in a positive way in the short term but somehow I have little hope of that happening.